Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.48 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9277650 | 0.94 | LRRK2 (0.51) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL9279742 | 0.92 | LRRK2 (0.51) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL9276955 | 0.92 | LRRK2 (0.51) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL9277106 | 0.92 | LRRK2 (0.51) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL9273876 | 0.89 | LRRK2 (0.51) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL9276144 | 0.89 | LRRK2 (0.49) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL9280420 | 0.88 | PTK2 (0.52) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL9273889 | 0.87 | LRRK2 (0.48) | LRRK2PTK2JAK2NTRK1TYK2 | |
| SCHEMBL9281228 | 0.86 | ALK (0.54) | LRRK2ALK | |
| SCHEMBL9277522 | 0.85 | ALK (0.49) | LRRK2ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646448-B1 | MACROCYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9133224-B2 | Macrocyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2646448-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130261086-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2012074951-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261086-A1 | MACROCYCLIC KINASE INHIBITORS | PTK2, SRC, PTK2B | LRRK2 707/4885PTK2 1/4885JAK2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.